Evidence supporting the use of: Paeoniflorin
For the health condition: Chronic Obstructive Pulmonary Disorder

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Paeoniflorin and Chronic Obstructive Pulmonary Disease (COPD): Evidence Synopsis

Paeoniflorin is a bioactive compound primarily derived from the roots of Paeonia lactiflora, a plant used in traditional Chinese medicine. In recent years, scientific interest has grown around paeoniflorin due to its anti-inflammatory, immunomodulatory, and antioxidant properties. Several preclinical studies have explored its potential in respiratory diseases, including COPD.

Animal and cellular studies have demonstrated that paeoniflorin can reduce airway inflammation, inhibit oxidative stress, and downregulate inflammatory signaling pathways such as NF-κB and MAPK in COPD models. For example, research published in peer-reviewed journals has shown that paeoniflorin treatment can decrease lung tissue damage, reduce infiltration of inflammatory cells, and lower the levels of pro-inflammatory cytokines in rat models of COPD.

However, robust clinical evidence in humans is lacking. Most of the current data are limited to laboratory and animal studies; no large-scale randomized controlled trials have evaluated paeoniflorin’s efficacy or safety in COPD patients. Thus, while scientific rationale and preclinical findings support the potential of paeoniflorin as an adjunct in COPD management, its use is not yet validated by high-quality clinical evidence.

In summary, while there is a scientific basis for considering paeoniflorin in COPD, the current level of evidence is preliminary (rated 2/5) and primarily based on non-human studies.

More about paeoniflorin
More about Chronic Obstructive Pulmonary Disorder

Products containing paeoniflorin

We currently have no products on Vitabase that contain this ingredient.